Clinical trials: HIV -1 Infection
Hepatic Steatosis, HIV-1-infection
Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV
This is a multicentre, phase IV, randomised, open-label, trial exploring adjunctive maraviroc and/or metformin for liver steatosis over 48 weeks.
- Trial name
- MAVMET (NCT03129113)
- Testing
- Maraviroc, Metformin
- Where
- 6 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- University College, London
HIV-1-infection
Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).
Multicenter, parallel group, randomised, open label, study. Twenty-five clinical centers constituting the InAction network will participate the study.
- Trial name
- P25-INACTION (NCT04225325)
- Testing
- SYMTUZA, DESCOVY+DOLUTEGRAVIR, SYMTUZA+DOLUTEGRAVIR
- Where
- Italy
- Volunteers
- 112 people
- Sponsor
- ADRIANO LAZZARIN, MD
HIV Infections
A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the PGDM1400 and PGT121 and VRC07-523LS mAbs for HIV prevention and therapy.
- Trial name
- NCT03205917
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV-1-infection, Hypertension
Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
Social distancing measures put in place to combat the COVID-19 disease pandemic may increase social isolation and impact cardiovascular disease prevention behaviors among people living with HIV (PLWH).
- Trial name
- AAIM-High (NCT04661813)
- Testing
- EXTRA-CVD Virtual Care
- Where
- 3 sites in United States
- Volunteers
- 81 people
- Sponsor
- Case Western Reserve University
HIV Infections
A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)
The use of a Bioject 2000 needle free injection device (NFID) and a compressed immunization schedule will be safely tolerated and will augment the immunogenicity of the HIV-1 CTL epitope DNA vaccine (EP1090) in HIV-1 infected…
- Trial name
- EP1090 (NCT00532974)
- Testing
- EP1090
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Epimmune
HIV Infections
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
The purpose of this study is to test the safety of an HIV DNA vaccine (EP HIV-1090) and to test whether or not the vaccine can stimulate immune system responses in HIV uninfected people.
- Trial name
- NCT00054860
- Testing
- EP HIV-1090
- Where
- 5 sites in United States, Botswana
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Efficacy and Safety of Ainuovirine Treating With AIDS Patients
Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults.
- Trial name
- ESATA (NCT05420246)
- Testing
- Ainuovirine
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV Infections
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
This study evaluated the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons…
- Trial name
- NCT03560258
- Testing
- p24CE1/2 pDNA vaccine, p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine, Full-length p55^gag pDNA vaccine
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
ACTG A5275 was a prospective, double-blind, randomized, placebo-controlled cross-over design pilot study evaluating the effect of atorvastatin on biomarkers of inflammation, coagulopathy, angiogenesis, and T-lymphocyte activation…
- Trial name
- NCT01351025
- Testing
- atorvastatin
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
To evaluate the safety and immunogenicity of an accelerated schedule of recombinant canarypox vaccine ALVAC-HIV MN120TMG (vCP205) versus control followed by boost with rgp120/HIV-1 SF2 vaccine in HIV-negative volunteers.
- Trial name
- NCT00001076
- Testing
- ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
- Where
- 3 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections
A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients
To define relationships between 1) HIV load and risk of CMV disease, 2) CMV load and the risk of developing CMV disease, and 3) CMV load and HIV load.
- Trial name
- NCT00001089
- Where
- 36 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV/AIDS, HIV Infections
Proviral DNA as a Target for HIV-1 Resistance Analysis
In summary, in this project the investigators propose to study the proviral DNA genotyping to implement a lower cost and wider than the commercial systems currently in use, in order to analyze all HIV genes that are therapeutic…
- Conditions
- HIV/AIDS, HIV Infections, HIV Seropositivity, Viral Infection
- Trial name
- HIV (NCT04088916)
- Where
- 2 sites in Chile
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- University of Chile
HIV-1-infection
Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances
The investigators performed this study to evaluate the safety and feasibility of transplantation with CRISPR/Cas9 CCR5 gene modified CD34+ hematopoietic stem/progenitor cells for patients that develop AIDS and hematological…
- Trial name
- NCT03164135
- Testing
- CCR5 gene modification
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
HIV Infections
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
- Trial name
- NCT00675844
- Testing
- Elvucitabine
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Infection, Human Immunodeficiency Virus, HIV Infections
Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
Cabotegravir (CAB) long-acting (LA) is a promising candidate for human immunodeficiency virus (HIV) pre exposure prophylaxis (PrEP) due to its potent antiretroviral activity and infrequent dosing requirements.
- Trial name
- NCT02478463
- Testing
- Cabotegravir tablet 30 mg once daily for 28 days., Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV-1 Infection
Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated
This is a open controlled trial in which 48 HIV-1 patients successfully treated with EFV/FTC/TDF will be randomized to one of 4 groups in equal proportion between arms (1:1).
- Trial name
- NCT01529749
- Testing
- EFV/FTC/TDF + Losartan, EFV/FTC/TDF, FTC/TDF + MK-0518
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Felipe Garcia
Pregnancy, HIV-1-infection
Pre-Exposure Prophylaxis Dosing in Pregnancy to Optimize HIV Prevention (PREP-P)
This trial is a prospective, multi-center, randomized comparison study of 2 Pre-Exposure Prophylaxis (PrEP) pharmacokinetic (PK) dosing regimens from 1st trimester through 12 weeks following delivery (postpartum) to achieve study…
- Trial name
- NCT03834909
- Testing
- Standard dose Truvada®, Pregnancy-adjusted dose Truvada®
- Volunteers
- healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV-1-infection
Primary Infection Cohort
Open, prospective, multicenter French cohort study enrolling subjects aged of 15 years or more, during or immediately after HIV-1 primary infection.
- Trial name
- PRIMO (NCT03148964)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 2,800 people
- Sponsor
- ANRS, Emerging Infectious Diseases